We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Direct Effect Media/Illumina

Pentax

Provides endoscopic imaging devices and solutions read more Featured Products: More products

Events

27 Jul 2018 - 29 Jul 2018
25 Aug 2018 - 29 Aug 2018
29 Aug 2018 - 01 Sep 2018

Cryoablation System Effective for Esophageal Disorders

By HospiMedica International staff writers
Posted on 19 Jun 2018
Print article
Image: The C2 CryoBalloon ablation system (Photo courtesy of Pentax Medical).
Image: The C2 CryoBalloon ablation system (Photo courtesy of Pentax Medical).
A novel balloon cryosurgical tool treats Barrett's esophagus (BE) and esophageal squamous cell neoplasia (ESCN) effectively and with low patient discomfort.

The Pentax Medical (Tokyo, Japan) C2 CryoBalloon ablation system is a designed to ablate unwanted tissue by application of extreme cold during endoscopy. The system is comprised of a sterile balloon catheter, a controller unit, and a nitrous oxide (NO) cartridge. Treatment sites are selected by adjusting endoscope and controller positions, with the tissue to be ablated then visualized through the inflated balloon. Once in contact with the tissue, the balloon is inflated with NO, rapidly cooling it and ablating unwanted tissue. The NO then exhausts through the controller.

Operation of the system is intuitive, fast (15-30 minutes per procedure), and cost-effective, and also eliminates the need for precise sizing and multiple deployment steps due to the real-time visualization of the esophagus during treatment. The system is compatible with commercially available endoscopes with a minimum working channel inner diameter of 3.7 mm and length of 100 cm. According to clinical studies, 95% of patients treated with the C2 CryoBalloon achieve complete eradication of dysplasia, and 90% have complete eradication of intestinal metaplasia through two years.

“We are committed to advancing the treatment of Barrett's esophagus with a new generation of ablation devices that are easy to use and improve clinical outcomes and patient satisfaction,” said David Woods, global chief marketing officer of Pentax Medical. “C2 CryoBalloon strengthens our therapeutic endoscopy portfolio and is an important technology that enables endoscopists to improve the quality of care they provide to their patients.”

Barrett’s Esophagus develops as a result of chronic injury from gastroesophageal reflux disease (GERD), which causes metaplasia of the normal squamous epithelium lining of the esophagus, replacing them with goblet cells, which are usually found lower in the gastrointestinal tract. The medical significance of BE is its strong association with esophageal adenocarcinoma, a particularly lethal form of cancer.

Cryoballoon technology offers shorter procedure times than point-by-point radiofrequency (RF) ablation, and better treatment outcomes than drug therapy. It has been shown to improve quality of life for patients and significantly reduce paroxysmal (sporadic) AF symptoms, such as palpitations, fatigue, rapid heartbeat, swelling, and syncope.


Print article
FIME - Informa
Radcal

Channels

Copyright © 2000-2018 Globetech Media. All rights reserved.